top of page
NS-Baseline2020_white.png

Your  R&D
department

Neuro-Sys is a research-intensive and innovative organization specializing in pharmacology and in advanced in vitro and in vivo models of neurodegenerative diseases, mode of action research, and drug development in the CNS and PNS fields.

Award winning CRO

Best Neurodegenerative Disease CRO 2024

Global Health Pharma

Dec. 2024

Oct24213_Neuro-Sys_Healthcare and Pharmaceutical Awards 2024_ (AI-GS1122-25) Glass Trophy

Experts in
neurodegenerative
preclinical modelling
services

Latest
news

News
Oct24213_Neuro-Sys_Healthcare and Pharmaceutical Awards 2024_Winners Badge.jpg

 AWARDS  December, 2024

🌟Neuro-Sys Honored with "Best Neurodegenerative Disease CRO 2024" Award! by Global Health Pharma🌟

We are proud to announce that Neuro-Sys has been awarded the prestigious title of "
Best Neurodegenerative Disease CRO 2024"! 🏆

This recognition is the result of the hard work and dedication of our talented team, who strive every day to deliver the highest quality studies in neurodegenerative disease research.
We would like to extend our heartfelt gratitude to each of our team members for their expertise, passion, and commitment. A special thanks to our clients for their trust and collaboration. It's because of you that we can continue to push the boundaries of research.

This award is not just an achievement; it is a springboard for new challenges and opportunities. We look forward to continuing our mission and reaching new heights together!

> More

 EVENT  September, 2024: 🚀 Neuro-Sys Takes Flight: Unveiling Our Cutting-Edge Research Hub!
 

We are thrilled to announce a transformative milestone in Neuro-Sys' journey! We've moved into our new state-of-the-art facility, spanning an impressive 2,000 m² (approx. 20,000 sq ft). This expansion marks a quantum leap in our capabilities to drive innovation in neurodegenerative research.

Key highlights of our expansion:

  • 4x larger space, enabling simultaneous complex studies

  • A talented, specialized team of 40+ experts

  • Massive investment in cutting-edge equipment

  • Enhanced capacity for more robust and relevant studies


This move empowers us to deliver even more powerful, pertinent, and reliable studies to our valued clients in the pharmaceutical, biotech, and academic sectors.
We're excited to push the boundaries of neurodegenerative research further than ever before. Stay tuned for more updates as we embark on this thrilling new chapter!

20240930_154140.jpg
20241015_125537.png
20240730_111435.jpg

 EVENT  Winner of Neuro-Sys' Ball Game, AAIC 24, Philadelphia

Congratulations to Sasha Milton from University of California, San Francisco, who scored Phillies vs. Yankees tickets as part of NEURO-SYS’ AAIC24 giveaway! We hope that he'll enjoy the game and have an unforgettable experience at Citizens Bank Park.

Special thanks to everyone who participated and helped make our giveaway a success.

AAIC-2024_2.png

 POSTERS  July 28, 2024

Poster presentation @AAIC 2024

"Lecanemab induces phenotypic change in glial and microglial cells in Alzheimer's disease models: vitro and vivo evidences."

Poster # N6P48

> More

BIO-International-Convention.png

 EVENT  June 3-6, 2024, San Diego, CA

Neuro-Sys will attend the Bio International Convention.

Our CEO, CSO and VP of Business Development invite you to the partnering meetings and explore collaborative opportunities with Neuro-Sys!

> More

ALS-Drug-Development.png

 EVENT  May 21-23, 2024, Boston, MA

Neuro-Sys will sponsor and exhibit at the 3rd Annual ALS Drug Development Summit

> More

APDD-Logo.png

 EVENT  April 23-25, 2024, Boston, MA

Neuro-Sys will sponsor and exhibit at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit

Our CSO will be giving a talk on: "Parkinson’s disease: alpha-synuclein’s mechanisms of cell death in vitro and in vivo evidences"

> More

Cortex AI3_2.png

 INNOVATION  January 18, 2024

CORTEX AI project

Thanks to the innovative integration of artificial intelligence into Neuro-Sys processes, CORTEX AI promises to revolutionize neuroscientific studies with unmatched precision, efficiency, and speed. This advanced technology enables complex data analysis for a better understanding of the mechanisms of action in neurodegenerative diseases, offering new perspectives and solutions in this critical field.

> More

20231115_143838.jpg

 POSTERS  November 15, 2023

Poster presentation @SFN 2023

"Toxicity of amyloid beta oligomers involves chronic hyperphosphorylation of Tau: evidence from in vitro and in vivo models."

Poster # N6P45

20231114_105311.jpg

 POSTERS  November 14, 2023

Poster presentation @SFN 2023

"SOD1G93A mutation connects mitochondrial dysfunctions, neuromuscular junction disruption and increased sensitivity to glutamatergic stress in in vitro models of ALS."

Poster # N6P44

Jul23558_Neuro-Sys_GHP_Healthcare & Pharma_2023_TD-TP07C_Trophy x1.png

 AWARDS  October, 2023

We are proud to announce that Neuro-Sys has been awarded

"Best CRO of the Year 2023" for Europe by Global Health & Pharma (UK).


This is a tribute to the quality work of our teams and the excellence of our scientific integrity that we offer to our clients and partners every day.

> More

MnM3.png

 EVENT  October 9-10, 2023, London, UK

Neuro-Sys will sponsor and exhibit at the 6th Annual Neuroscience R&D Conference

 

Our CSO will be giving a talk on:

"Parkinson’s disease: alpha-synuclein toxicity and spreading, in vitro and in vivo models."

design Book

 PUBLICATIONS  August 30, 2022

Alpha-Synuclein: The Spark That Flames Dopaminergic Neurons, In Vitro and In Vivo Evidence

Alexandre Henriques, Laura Rouvière, Elodie Giorla, Clémence Farrugia, Bilal El Waly, Philippe Poindron and Noelle Callizot

> More

ijms-23-08867-g001.png

 PUBLICATIONS  August 09, 2022

NX210c Peptide Promotes Glutamatergic Receptor-Mediated Synaptic Transmission and Signaling in the Mouse Central Nervous System

Sighild Lemarchant, Mélissa Sourioux, Juliette Le Douce, Alexandre Henriques, Noelle Callizot, Sandrine Hugues, Mélissa Farinelli and Yann Godfrin

> More

20220801_104623.png

 POSTERS  August 01, 2022

Poster presentation @AAIC 2022

"Neuroinflammation and microglial activation in Alzheimer’s Disease: in vitro and in vivo models of study."

Poster # N6P42

20220713_095924.jpg

 POSTERS  July 13, 2022

Poster presentation @FENS 2022

"New in vivo model of Parkinson’s disease involving combined toxicity of alpha-synuclein oligomers and protofibrils, and chronic inhibition of GBA."

Poster # N6P41

FENS2022_1.png

 POSTERS  July 12, 2022

Poster presentation @FENS 2022

"Loss of GBA activity exacerbate the toxicity of alpha-synuclein oligomers and protofibrils in an in vitro model of Parkinson’s disease."

Poster # N6P40

News_award.png

 AWARDS  August 29, 2021

 

Neuro-Sys inc. elected 2021 World's Best CRO of the year by Corporate Live Wire (UK).

We are very proud of this distinction, which congratulates several years of preclinical scientific excellence, the continuous efforts of our team of experts and the significant investments undertaken.

> More

design Book

 PUBLICATIONS  August 30, 2021

NSP01, a green extract of Huperzia serrata with neuroprotective effects related to synergistic action of Huperzine A and polyphenols

Noelle Callizot, Maria-Letizia Campanari, Laura Rouvière, Guillaume Jacquemot, Alexandre Henriques, Elnur Garayev and Philippe Poindron

> More

design Book

 PUBLICATIONS  August 19, 2021

AZP2006, a new promising treatment for Alzheimer’s and related diseases

N Callizot, C Estrella, S Burlet, A Henriques, C Brantis, M Barrier, M L Campanari, P Verwaerde

> More

News_PD.png

 PLATFORMS  March 8, 2021

 

The histology department is strengthened with the reinforcement of the team and the investment in the latest equipment.

> More

Biomek_edited.jpg
bottom of page